Max Robotics — Global Service Robot Directory + US Certification

About

William Greenhalf is a leading translational researcher whose work bridges genetics and oncology, with a primary focus on pancreatic disease and cancer treatment optimization. His early landmark study, "Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers" (2005, 114 citations), fundamentally advanced our understanding of how CFTR gene mutations—even in carriers—significantly elevate the risk of chronic pancreatitis, establishing a critical link between cystic fibrosis genetics and pancreatic pathology. This work has been instrumental in shaping clinical risk assessment for idiopathic pancreatitis. More recently, Greenhalf has made pivotal contributions to head and neck oncology through the PATHOS trial (2018), a phase II/III study investigating risk-stratified, reduced-intensity adjuvant treatment following transoral surgery for HPV-positive oropharyngeal cancer. This trial addresses the urgent need to minimize long-term toxicities while maintaining excellent survival outcomes in this rapidly growing patient population. His research exemplifies the power of integrating genetic risk stratification with personalized treatment de-escalation strategies, directly impacting clinical practice and patient quality of life.